Overview: PCNA TestIntroduction: The PCNA Test tests for PCNA expression to assess cell proliferation in cancers, helping diagnose or monitor tumors causing abnormal growth. Affecting 1 in 100 people with cancer, PCNA expression poses diagnostic challenges due to tumor variability. Following 2023 National Comprehensive Cancer Network (NCCN) guidelines, it uses immunohistochemistry for high accuracy, supporting histopathology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in oncology.
Other Names: PCNA Expression Test, Proliferation Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic reliability.
Historical Milestone: PCNA testing began in the 1980s with research by Celis, who identified the protein. Immunohistochemistry advancements in the 1990s by Dako improved detection, surpassing earlier manual methods.
Purpose: Detects PCNA expression to diagnose or monitor cancer, guides chemotherapy or targeted therapy, and evaluates patients with abnormal growth, aiming to manage disease.
Test Parameters: PCNA expression
Pretest Condition: Tissue biopsy required. Collect tissue. Report history of cancer.
Specimen: Tissue (FFPE, 0.5-2 cma³); Tissue in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document cancer history or abnormal growth. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., metastasis), and sample collection risks.
Procedural Considerations: Uses immunohistochemistry to detect expression, requiring labs with staining facilities. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: High expression suggests active cancer, guiding therapy. Early treatment might improve survival, while untreated cases lead to progression. Normal levels may require other tests.
Specialist Consultation: Consult an oncologist for interpretation.
Additional Supporting Tests: Biopsy, CT scan, or Ki-67 test to confirm diagnosis.
Test Limitations: Non-specific for cancer type; correlation with imaging needed. False negatives possible with low expression.
References: NCCN Guidelines, 2023; Cancer Research, Celis JE, 2022.
